Transfusion & Transplantation Technologies (3Ti) is a pre-revenue stage in-vitro diagnostics company developing novel automated blood testing instrumentation and associated consumables and services for the pre-transfusion (immunohematology) market worldwide. Our initial product, the Aegis Blood Analyzer and System, is being designed to perform highly accurate, rapid and cost-effective blood grouping (ABO and Rh), red cell antibody screening/identification and certain donor/recipient cross-matching tests—all with walk-away automation. We believe the Aegis System will prove to be attractive to blood collection centers, hospital labs and certain clinical laboratories contemplating automation for the first time (a majority of blood bank testing sites today). We also believe the Aegis System will prove particularly attractive to currently automated blood bank sites demanding both next generation performance and features in their automated analyzer. Our Mission: “To become the standard of care in automated blood bank testing worldwide.”

We believe the Aegis System to be the first to successfully incorporate fully automated flow cytometry and fluorescently labeled antibodies into a single integrated blood bank analyzer. Flow

cytometry has been widely acknowledged within the research and scientific communities as a technology with significant advantages over other diagnostic and immunoassay testing platforms: speed, exquisite precision and the ability to use micro-sampling on a multitude of analytes from not only a sample but also a single cell. As a result, the Aegis System has the potential to perform 1) a full menu of routine blood bank tests; 2) certain tests that have still remained “un-automatable” on today’s automated platforms (e.g., rWBC); and 3) potentially new and emerging tests and/or testing platforms going forward. The Company has filed 15 patents associated with its technology to date with two patents having issued. We intend to aggressively defend and expand our patent portfolio going forward.

The Aegis System was presented to the Center for Biologics Evaluation and Research (CBER) division of FDA in late 2007 for early directional evaluation of protocols and plans for clinical evaluations. Plans for clinical evaluations include several sites in 2008 and submission to FDA for 510k clearance shortly thereafter.

The Company is in the process of securing outside financing and exploring strategic partnerships to accelerate and complete Aegis System development and commercialization.

For "Research Use Only"